Novan, a late-stage biotech developing nitric oxide based therapies for dermatologic indications, filed on Wednesday with the SEC to raise up to $60 million in an initial public offering.
The Durham, NC-based company was founded in 2006 and plans to list on the Nasdaq under the symbol NOVN. Piper Jaffray is the sole bookrunner on the deal. No pricing terms were disclosed.
